[1] ENSRUD KE, CRANDALL CJ. Osteoporosis. Ann Intern Med. 2017;16(7): 17-32.
[2] DELGADO-CALLE J, SATO AY, BELLIDO T. Role and mechanism of action of sclerostin in bone. Bone. 2017;96(4):29-37.
[3] EASTELL R, SZULC P. Use of bone turnover markers in postmenopausal osteoporosis. Lancet Diabetes Endocrinol. 2017;5(12):908-923.
[4] KHOSLA S, HOFBAUER LC. Osteoporosis treatment: recent developments and ongoing challenges. Lancet Diabetes Endocrinol. 2017;5:898-907.
[5] KRISTENSEN LS, ANDERSEN MS, STAGSTED LV, et al. The biogenesis, biology and characterization of circular RNAs. Nat Rev Genet. 2019; 20(9):675-691.
[6] MONTALCINI T, ROMEO S, FERRO Y, et al. Osteoporosis in chronic inflammatory disease: the role of malnutrition. Endocrine. 2013; 43(11):59-64.
[7] ADLER RA, FULEIHAN EH, BAUER DC, et al. Managing osteoporosis patients after long-term bisphosphonate treatment: report of a task force of the american society for bone and mineral research. J Bone Miner Res. 2016;31(1):16-35.
[8] FORCIEA MA, MCLEAN RM, QASEEM A. Treatment of low bone density or osteoporosis to prevent fractures in men and women: a clinical practice guideline update from the american college of physicians. Ann Intern Med. 2017;167(12):899-910.
[9] JORDAN VC, MORROW M. Raloxifene as a multifunctional medicine? Current trials will show whether it is effective in both osteoporosis and breast cancer. BMJ. 2019;19(29):331-339.
[10] GENNARI L, ROTATORI S, BIANCIARDI S, et al. Treatment needs and current options for postmenopausal osteoporosis. Expret Opin Pharmacother. 2016;17(8):1141-1152.
[11] KOCIJAN R, MUSCHITZ C, GEIGER E, et al. Circulating microRNA signatures in patients with idiopathic and postmenopausal osteoporosis and fragility fractures. J Clin Endocrinol Metab. 2016; 101(11):4125-4134.
[12] PASCHALIS EP, GAMSJAEGER S, HASSLER N, et al. Vitamin D and calcium supplementation for three years in postmenopausal osteoporosis significantly alters bone mineral and organic matrix quality. Bone. 2017;95(9):41-46.
[13] LI J, YANG J, ZHOU P, et al. Circular RNAs in cancer: novel insights into origins, properties, functions and implications. Am J Cancer Res. 2015;5:472-480.
[14] KULCHESKI FR, CHRISTOFF AP, MARGIS R. Circular RNAs are miRNA sponges and can be used as a new class of biomarker. J Biotechnol. 2016;238(3):42-51.
[15] VALENTI MT, DALLE CARBONARE L, MOTTES M. Osteogenic differentiation in healthy and pathological conditions. Int J Mol Sci. 2016;18(6):41-49.
[16] 中华医学会.临床诊疗指南·骨质疏松症和骨矿盐疾病分册[M].北京:人民卫生出版社,2010:1-7.
[17] FLORIS G, ZHANG L, FOLLESA P, et al. Regulatory role of circular RNAs and neurological disorders. Mol Neurobiol. 2017;54(7):5156-5165.
[18] ARLOT M, EDOUARD C, MEUNIER PJ, et al. Impaired osteoblast function in osteoporosis: comparison between calcium balance and dynamic histomorphometry. Br Med J. 2019;289(6444):517-520.
[19] CHEUNG CL, ANG SB, CHADHA M, et al. An updated hip fracture projection in Asia: the Asian Federation of Osteoporosis Societies study. Osteoporosis Sarcopenia. 2018;4(1):6-21.
[20] PALAK C, JEPSEN KJ, CLINES GA. The challenges of diagnosing osteoporosis and the limitations of currently available tools. Clin Diabetes Endocrinol. 2018;4(1):12-17.
[21] DU WW, FANG L, YANG W, et al. Induction of tumor apoptosis through a circular RNA enhancing Foxo3 activity. Cell Death Differ. 2017;24(2):357-370.
[22] ZHAO K, ZHAO Q, GUO Z, et al. Hsa_Circ_0001275: a potential novel diagnostic biomarker for postmenopausal osteoporosis. Cell Physiol Biochem. 2018;46(6):2508-2516.
[23] CAI Q, ZHENG P, MA F, et al. MicroRNA-224 enhances the osteoblastic differentiation of hMSCs via Rac1. Cell Biochem. 2019;37(8):62-71.
[24] LI M, LUO R, YANG W, et al. miR-363-3p is activated by MYB and regulates osteoporosis pathogenesis via PTEN/PI3K/AKT signaling pathway. Dev Biol Anim. 2019;55(12):376-386.
[25] CHEN R, QIU H, TONG Y, et al. MiRNA-19a-3p alleviates the progression of osteoporosis by targeting HDAC4 to promote the osteogenic differentiation of hMSCs. Biochem Biophys Res Commun. 2019;516(3):666-672.
[26] NICOLET BP, ENGELS S, AGLIALORO F, et al. Circular RNA expression in human hematopoietic cells is widespread and cell type specific. Nucleic Acids Res. 2018;46(16):8168-8180.
[27] CHERUBINI A, BARILANI M, ROSSI RL, et al. FOXP1 circular RNA sustains mesenchymal stem cell identity via microRNA inhibition. Nucleic Acids Res. 2019;47(10):5325-5340.
[28] SHEN W, SUN B, ZHOU C, et al. CircFOXP1/FOXP1 promotes osteogenic differentiation in adipose erived mesenchymal stem cells and bone regeneration in osteoporosis via miR-33a-5p. J Cell Mol Med, 2020; 24(21):12513-12524.
[29] YU L, LIU Y. circRNA_0016624 could sponge miR-98 to regulate BMP2 expression in postmenopausal osteoporosis. Biochem Biophys Res Commun. 2019;516(2):546-550.
[30] HUANG Y, XIE J, LI E. Comprehensive circular RNA profiling reveals circ_0002060 as a potential diagnostic biomarkers for osteoporosis. J Cell Biochem. 2019;120(9):15688-15694.
[31] ZHAO K, ZHAO Q, GUO Z, et al. Hsa_Circ_0001275: a potential novel diagnostic biomarker for postmenopausal osteoporosis. Cell Physiol Biochem. 2018;46(6):2508-2516.
|